Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New nasal nerve device shows promise for stuffy noses

NCT ID NCT06128200

Symptom relief Sponsor: Neurent Medical Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed trial tested the NEUROMARK device, which uses radiofrequency to disrupt nerves in the nose, against a sham (fake) procedure in 132 adults with chronic rhinitis. The goal was to see if the device could reduce symptoms like runny nose and congestion by at least 30% after 90 days. Participants had moderate to severe symptoms for at least 6 months before joining.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NEUROMARK System (device that uses radiofrequency to disrupt posterior nasal nerves)
What this could lead to
If it works, this could offer a long-lasting, non-drug option to reduce runny nose and congestion in people with chronic rhinitis.
What could go wrong
This is a completed trial with 132 participants, but results are not yet widely confirmed. The procedure is invasive and may cause temporary discomfort or side effects like nosebleeds or pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

132 people

The number who actually took part.

Started

Oct 2023

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participant Must: 1. Be ≥18 years of age. 2. Have been experiencing rhinitis symptoms for a minimum of 6 months. 3. Have moderate to severe symptoms of runny nose (individual rTNSS symptom rating of 2 or 3), mild to severe symptoms of nasal congestion (individual rTNSS symptom rating of 1,2, or 3), and a minimum total score of 5 (out of 12) at baseline. 4. Be an appropriate candidate for bilateral NEUROMARK device treatment performed under local anesthesia. 5. Be willing and able to comply with all study elements, as indicated by written informed consent. Primary Exclusion Criteria: Participant Must Not: 1. Have clinically significant anatomic obstruction that in the investigator's opinion limit access to the posterior nose, including but not limited to severe septal deviation or perforation, nasal polyps, and/or sinonasal tumor. 2. Have had previous sinus or nasal surgery within 6 months of study enrollment. 3. Have previously undergone RF, cryotherapy, or other surgical interventions for rhinitis. 4. Have rhinitis symptoms that are due to seasonal allergies only.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic rhinitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic rhinitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic rhinitis

Contacts and locations

Locations

  • Advanced ENT & Allergy

    Louisville, Kentucky, 40220, United States

  • Ascension St. Vincent

    Anderson, Indiana, 46016, United States

  • Bethlehem ENT

    Bethlehem, Pennsylvania, 18017, United States

  • Breathe Clear Institute

    Torrance, California, 90503, United States

  • Centers for Advanced ENT Care

    Baltimore, Maryland, 21204, United States

  • ENT & Allergy Associates

    Puyallup, Washington, 98374-1145, United States

  • ENT & Allergy Associates of Florida

    Boynton Beach, Florida, 33426, United States

  • ENT & Allergy Associates of Florida

    Port Saint Lucie, Florida, 34952, United States

  • East Alabama ENT

    Opelika, Alabama, 36801, United States

  • ExcelENT

    Homewood, Alabama, 35204, United States

  • Houston Methodist ENT Specialists

    Houston, Texas, 77030, United States

  • Kentuckiana

    Louisville, Kentucky, 40205, United States

  • Richmond ENT

    Richmond, Virginia, 23235, United States

  • Sacramento ENT

    Sacramento, California, 95815, United States

  • Sensa Health

    Los Angeles, California, 90006, United States

  • The ENT & Allergy Centers of Texas

    McKinney, Texas, 75708, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.